CurrentCignaPolicy N/A

Parkinson's Disease Vyalev Prior Authorization Policy

Prior authorization policy for coverage of Vyalev (continuous subcutaneous infusion of foscarbidopa and foslevodopa) for adults with advanced Parkinson's disease under Cigna-administered health benefit plans.

Policy Summary

PayerCigna

PolicyParkinson's Disease Vyalev Prior Authorization Policy

Policy CodePolicy N/A

Change TypeNo material changes

Effective Date

Next Review DateOct 22, 2025

Key ActionObtain prior authorization and document that patient has advanced Parkinson's disease, 'off' episodes, prior oral carbidopa/levodopa trial with intolerance or inadequate efficacy, trial of another 'off' episode treatment, and prescription by or in consultation with a neurologist.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

1 yearapproval duration

neurologistprescriber requirement

requiredprior oral trial

requiredother 'off' treatment

not addressedguideline status

Policy Summary

PayerCigna

PolicyParkinson's Disease Vyalev Prior Authorization Policy

Policy CodePolicy N/A

Change TypeNo material changes

Effective Date

Next Review DateOct 22, 2025

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

FDA‑Approved Indication

Covered when ALL of the following are met for the FDA‑approved indication (approve for 1 year):

Vyalev FDA‑approved indication criteria: A) Patient is diagnosed with advanced Parkinson's disease; AND B) Patient is experiencing 'off' episodes such as muscle stiffness, slow movements, or difficulty starting movements; AND C) Patient has tried an oral carbidopa/levodopa therapy and meets ONE of the following: (i) significant intolerance per prescriber OR (ii) inadequate efficacy per prescriber; AND D) Patient has previously tried or is currently receiving ONE other treatment for 'off' episodes (examples include entacapone, rasagiline, pramipexole, ropinirole, tolcapone, cabergoline, selegiline, Ongentys (opicapone), or Xadago (safinamide)); AND E) The medication is prescribed by or in consultation with a neurologist.approve for 1 year

Prescriber specialty requirement and prior treatment trials required

The policy’s "Conditions Not Covered" section specifically lists Vyalev (foscarbidopa and foslevodopa subcutaneous injection – AbbVie). The document does not further enumerate specific excluded diagnoses or alternative exclusions under that heading, so no additional non‑covered conditions are detailed in the source.

There is no statement in the policy aligning Vyalev to or excluding it from existing international Parkinson’s disease treatment guidelines; the background notes that current guideline reviews do not specifically address Vyalev, so unresolved guideline alignment remains (the policy neither endorses nor rejects guideline incorporation for this product).

Provider Requirements, Prior Authorization, and Billing

Prior Authorization

Prior authorization required — approve for 1 year if all FDA‑approved criteria met

Prior authorization is recommended for Vyalev (foscarbidopa and foslevodopa). Approvals are provided for 1 year when all FDA‑approved indication criteria are met, including diagnosis of advanced Parkinson's disease and the other criteria (A–E).

Step Therapy

Required prior medication trials for 'off' episodes

Patient must have tried an oral carbidopa/levodopa therapy and either had significant intolerance or inadequate efficacy per the prescriber, and must have previously tried or be currently receiving one other treatment for 'off' episodes (examples listed).

Oral carbidopa/levodopa trial with either: significant intolerance (per prescriber) OR inadequate efficacy (per prescriber).
Trial or current use of one other treatment for 'off' episodes (examples: entacapone, rasagiline, pramipexole, ropinirole, tolcapone, cabergoline, selegiline, Ongentys (opicapone), Xadago (safinamide)).

Documentation Required

Prescriber requirement and authorization duration

Vyalev must be prescribed by or in consultation with a physician who specializes in the condition being treated (neurologist); approvals are provided for the duration noted in the policy.

Prescriber specialty requirement: neurologist or consultation with a neurologist.
Authorization duration: approvals provided for 1 year when criteria are met.

Denial Risk

Coverage and billing compliance — risk of denial

Claims submitted without covered diagnosis or procedure codes, or not submitted in accordance with the relevant coverage criteria, will be denied as not covered.

When billing, use the most appropriate codes as of the effective date of submission.
Services billed for conditions or diagnoses not covered under this policy will be denied.

Background

Vyalev is a continuous subcutaneous infusion formulation combining foscarbidopa and foslevodopa indicated for the treatment of motor fluctuations in adults with advanced Parkinson’s disease. It is intended to treat "off" episodes—periods of increased motor symptoms such as stiffness, slowness, or difficulty initiating movement.

For coverage, the policy requires meeting the FDA‑approved indication criteria (approve for 1 year) which include diagnosis of advanced Parkinson’s disease, presence of "off" episodes, a prior trial of oral carbidopa/levodopa with documented intolerance or inadequate efficacy, trial or current use of at least one other treatment for "off" episodes, and that the medication be prescribed by or in consultation with a neurologist.

Key Definitions

inv-08: advanced Parkinson's disease

DefinitionParkinson's disease stage for which Vyalev is indicated; patient must be diagnosed with advanced Parkinson's disease to meet coverage criteria.

Policy requirementPatient must be diagnosed with advanced Parkinson's disease (required to satisfy FDA‑approved indication criteria).

Related coverage noteApproval for the FDA‑approved indication is for 1 year when all criteria are met.

Prescriber requirementMedication must be prescribed by or in consultation with a neurologist as part of the coverage criteria.

inv-09: 'off' episodes

DefinitionEpisodes associated with motor fluctuations characterized by muscle stiffness, slow movements, or difficulty starting movements.

Policy contextPresence of 'off' episodes is a required element of the FDA‑approved indication for Vyalev coverage.

Examples of related treatmentsPolicy lists example treatments for 'off' episodes (entacapone, rasagiline, pramipexole, ropinirole, tolcapone, cabergoline, selegiline, Ongentys [opicapone], Xadago [safinamide]).

Role in prior therapy requirementsPatient must have previously tried or be currently receiving one other treatment for 'off' episodes to meet coverage criteria.

OpenPayer

Parkinson's Disease Vyalev Prior Authorization Policy

Coverage Criteria for Vyalev (foscarbidopa and foslevodopa)

Provider Requirements, Prior Authorization, and Billing

Background

Key Definitions